Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  300 results for ""Cyclic Nucleotide Phosphodiesterases, Type 2""

Your Filters

Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Comprehensive analysis of PDE2A: a novel biomarker for prognostic value and immunotherapeutic potential in human cancers.

  • Authors : Yu Z; Nankai University Affinity the Third Central Hospital, Tianjin Third Central Hospital, Tianjin, China.; Song Y

Subjects: Cyclic Nucleotide Phosphodiesterases, Type 2*/Cyclic Nucleotide Phosphodiesterases, Type 2*/Cyclic Nucleotide Phosphodiesterases, Type 2*/genetics ; Cyclic Nucleotide Phosphodiesterases, Type 2*/Cyclic Nucleotide Phosphodiesterases, Type 2*/Cyclic Nucleotide Phosphodiesterases, Type 2*/metabolism ; Biomarkers, Tumor*/Biomarkers, Tumor*/Biomarkers, Tumor*/analysis

  • Source: Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas [Braz J Med Biol Res] 2024 Dec 13; Vol. 57, pp. e14220. Date of Electronic Publisher: Associação Brasileira de Divulgação Científica Country of Publication: Brazil NLM ID: 8112917 Publication Model: eCollection Cited

Record details

Read More Add to Saved list
×
Academic Journal

Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017-present).

Subjects: Patents as Topic* ; Cyclic Nucleotide Phosphodiesterases, Type 2*/Cyclic Nucleotide Phosphodiesterases, Type 2*/Cyclic Nucleotide Phosphodiesterases, Type 2*/antagonists & inhibitors ; Cyclic Nucleotide Phosphodiesterases, Type 2*/Cyclic Nucleotide Phosphodiesterases, Type 2*/Cyclic Nucleotide Phosphodiesterases, Type 2*/metabolism

  • Source: Expert opinion on therapeutic patents [Expert Opin Ther Pat] 2024 Nov; Vol. 34 (11), pp. 1105-1119. Date of Electronic Publication: 2024 Oct 09.Publisher: Informa Healthcare Country of Publication: England NLM ID: 9516419 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Effects of the phosphodiesterase 2 inhibitor BI 474121 on central nervous system cyclic guanosine monophosphate concentrations: Translational studies.

Subjects: Cyclic GMP*/Cyclic GMP*/Cyclic GMP*/cerebrospinal fluid ; Cyclic GMP*/Cyclic GMP*/Cyclic GMP*/metabolism ; Cyclic GMP*/Cyclic GMP*/Cyclic GMP*/blood

  • Source: British journal of clinical pharmacology [Br J Clin Pharmacol] 2024 Oct; Vol. 90 (10), pp. 2517-2528. Date of Electronic Publication: 2024 Jun 16.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Gene therapy with phosphodiesterases 2A and 4B ameliorates heart failure and arrhythmias by improving subcellular cAMP compartmentation.

  • Authors : Pavlaki N; Institute of Experimental Cardiovascular Research, University Medical Center Hamburg-Eppendorf, Martinistr. 52, D-20246 Hamburg, Germany.; DZHK (German Center for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, Martinistr. 52, D-20246 Hamburg, Germany.

Subjects: Cyclic AMP*/Cyclic AMP*/Cyclic AMP*/metabolism ; Heart Failure*/Heart Failure*/Heart Failure*/enzymology ; Heart Failure*/Heart Failure*/Heart Failure*/genetics

  • Source: Cardiovascular research [Cardiovasc Res] 2024 Jul 31; Vol. 120 (9), pp. 1011-1023.Publisher: Oxford Journals Country of Publication: England NLM ID: 0077427 Publication Model: Print Cited Medium: Internet ISSN: 1755-3245

Record details

Read More Add to Saved list
×
Academic Journal

Modulation of cAMP/cGMP signaling as prevention of congenital heart defects in Pde2A deficient embryos: a matter of oxidative stress.

  • Authors : Cardarelli S; Department of Anatomical, Histological, Forensic and Orthopaedic Sciences, Sapienza University of Rome, 00161, Rome, Italy.; Biglietto M

Subjects: Cyclic Nucleotide Phosphodiesterases, Type 2*/Cyclic Nucleotide Phosphodiesterases, Type 2*/Cyclic Nucleotide Phosphodiesterases, Type 2*/genetics ; Cyclic Nucleotide Phosphodiesterases, Type 2*/Cyclic Nucleotide Phosphodiesterases, Type 2*/Cyclic Nucleotide Phosphodiesterases, Type 2*/metabolism ; Heart Defects, Congenital*/Heart Defects, Congenital*/Heart Defects, Congenital*/genetics

  • Source: Cell death & disease [Cell Death Dis] 2024 Feb 23; Vol. 15 (2), pp. 169. Date of Electronic Publication: 2024 Feb 23.Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101524092 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

The phosphodiesterase 2A controls lymphatic junctional maturation via cGMP-dependent notch signaling.

  • Authors : Carlantoni C; Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany; German Centre of Cardiovascular Research (DZHK), Partner Site Hamburg/Luebeck/Kiel, Hamburg, Germany.

Subjects: Cyclic Nucleotide Phosphodiesterases, Type 2*/Cyclic Nucleotide Phosphodiesterases, Type 2*/Cyclic Nucleotide Phosphodiesterases, Type 2*/genetics ; Cyclic Nucleotide Phosphodiesterases, Type 2*/Cyclic Nucleotide Phosphodiesterases, Type 2*/Cyclic Nucleotide Phosphodiesterases, Type 2*/metabolism ; Lymphatic Vessels*/Lymphatic Vessels*/Lymphatic Vessels*/metabolism

  • Source: Developmental cell [Dev Cell] 2024 Feb 05; Vol. 59 (3), pp. 308-325.e11. Date of Electronic Publication: 2023 Dec 29.Publisher: Cell Press Country of Publication: United States NLM ID: 101120028 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Phosphodiesterase 2 and Its Isoform A as Therapeutic Targets in the Central Nervous System Disorders.

  • Authors : Metkar SK; Department of Anesthesiology, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ 07103, USA.; Yan Y

Subjects: Central Nervous System Diseases*/Central Nervous System Diseases*/Central Nervous System Diseases*/drug therapy ; Central Nervous System Diseases*/Central Nervous System Diseases*/Central Nervous System Diseases*/enzymology ; Cyclic Nucleotide Phosphodiesterases, Type 2*/Cyclic Nucleotide Phosphodiesterases, Type 2*/Cyclic Nucleotide Phosphodiesterases, Type 2*/metabolism

  • Source: CNS & neurological disorders drug targets [CNS Neurol Disord Drug Targets] 2024; Vol. 23 (8), pp. 941-955.Publisher: Bentham Science Publishers Country of Publication: United Arab Emirates NLM ID: 101269155 Publication Model: Print Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

CRISPR/Cas9 Knock-Out in Primary Neonatal and Adult Cardiomyocytes Reveals Distinct cAMP Dynamics Regulation by Various PDE2A and PDE3A Isoforms.

  • Authors : Skryabin EB; Institute of Experimental Cardiovascular Research, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.; De Jong KA

Subjects: CRISPR-Cas Systems*/CRISPR-Cas Systems*/CRISPR-Cas Systems*/genetics ; Myocytes, Cardiac*/Myocytes, Cardiac*/Myocytes, Cardiac*/metabolism ; Cyclic Nucleotide Phosphodiesterases, Type 2*/Cyclic Nucleotide Phosphodiesterases, Type 2*/Cyclic Nucleotide Phosphodiesterases, Type 2*/metabolism

  • Source: Cells [Cells] 2023 Jun 04; Vol. 12 (11). Date of Electronic Publication: 2023 Jun 04.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409

Record details

Read More Add to Saved list
×
Academic Journal

PDE2A Inhibition Enhances Axonal Sprouting, Functional Connectivity, and Recovery after Stroke.

  • Authors : Bechay KR; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California 90095.; Abduljawad N

Subjects: Stroke*/Stroke*/Stroke*/drug therapy ; Cyclic Nucleotide Phosphodiesterases, Type 2*/Cyclic Nucleotide Phosphodiesterases, Type 2*/Cyclic Nucleotide Phosphodiesterases, Type 2*/antagonists & inhibitors; Animals

  • Source: The Journal of neuroscience : the official journal of the Society for Neuroscience [J Neurosci] 2022 Nov 02; Vol. 42 (44), pp. 8225-8236. Date of Electronic Publication: 2022 Sep Publisher: Society for Neuroscience Country of Publication: United States NLM ID: 8102140 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Discovery of novel N-1 substituted pyrazolopyrimidinones as potent, selective PDE2 inhibitors.

  • Authors : Morriello GJ; Discovery Chemistry, Merck & Co., Inc., 2000 Galloping Hill Rd., Kenilworth, NJ 07033, USA. Electronic address: .; Dwyer MP

Subjects: Drug Discovery*; Cyclic Nucleotide Phosphodiesterases, Type 2/Cyclic Nucleotide Phosphodiesterases, Type 2/Cyclic Nucleotide Phosphodiesterases, Type 2/*antagonists & inhibitors ; Phosphodiesterase Inhibitors/Phosphodiesterase Inhibitors/Phosphodiesterase Inhibitors/*pharmacology

  • Source: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2021 Jul 15; Vol. 44, pp. 128082. Date of Electronic Publication: 2021 May 13.Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9107377 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-10 of  300 results for ""Cyclic Nucleotide Phosphodiesterases, Type 2""